Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib
Nature Methods2005Vol. 2(5), pp. 357–362
Citations Over TimeTop 10% of 2005 papers
Celia R. Berkers, Martijn Verdoes, Eben I. Lichtman, Edda Fiebiger, Benedikt M. Kessler, Kenneth C. Anderson, Hidde L. Ploegh, Huib Ovaa, Paul J. Galardy
Related Papers
- → Probing the Specificity and Activity Profiles of the Proteasome Inhibitors Bortezomib and Delanzomib(2012)51 cited
- → Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo(2019)14 cited
- → Bortezomib:a proteasome inhibitor in the treatment of multiple myeloma(2008)
- → Mechanism of resistance to proteasome inhibitor bortezomib in multiple myeloma(2016)
- → Mechanisms of proteasome inhibitor bortezomib on the therapy of multiple myeloma(2011)